File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Potential metabolite markers of schizophrenia

TitlePotential metabolite markers of schizophrenia
Authors
Keywordsbiomarker
GC-TOFMS
metaobonomics
NMR
schizophrenia
Issue Date2013
Citation
Molecular Psychiatry, 2013, v. 18, n. 1, p. 67-78 How to Cite?
AbstractSchizophrenia is a severe mental disorder that affects 0.5-1% of the population worldwide. Current diagnostic methods are based on psychiatric interviews, which are subjective in nature. The lack of disease biomarkers to support objective laboratory tests has been a long-standing bottleneck in the clinical diagnosis and evaluation of schizophrenia. Here we report a global metabolic profiling study involving 112 schizophrenic patients and 110 healthy subjects, who were divided into a training set and a test set, designed to identify metabolite markers. A panel of serum markers consisting of glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine was identified as an effective diagnostic tool, achieving an area under the receiver operating characteristic curve (AUC) of 0.945 in the training samples (62 patients and 62 controls) and 0.895 in the test samples (50 patients and 48 controls). Furthermore, a composite panel by the addition of urine β-hydroxybutyrate to the serum panel achieved a more satisfactory accuracy, which reached an AUC of 1 in both the training set and the test set. Multiple fatty acids and ketone bodies were found significantly (P0.01) elevated in both the serum and urine of patients, suggesting an upregulated fatty acid catabolism, presumably resulting from an insufficiency of glucose supply in the brains of schizophrenia patients. © 2013 Macmillan Publishers Limited.
Persistent Identifierhttp://hdl.handle.net/10722/342432
ISSN
2023 Impact Factor: 9.6
2023 SCImago Journal Rankings: 3.895
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYang, J.-
dc.contributor.authorChen, T.-
dc.contributor.authorSun, L.-
dc.contributor.authorZhao, Z.-
dc.contributor.authorQi, X.-
dc.contributor.authorZhou, K.-
dc.contributor.authorCao, Y.-
dc.contributor.authorWang, X.-
dc.contributor.authorQiu, Y.-
dc.contributor.authorSu, M.-
dc.contributor.authorZhao, A.-
dc.contributor.authorWang, P.-
dc.contributor.authorYang, P.-
dc.contributor.authorWu, J.-
dc.contributor.authorFeng, G.-
dc.contributor.authorHe, L.-
dc.contributor.authorJia, W.-
dc.contributor.authorWan, C.-
dc.date.accessioned2024-04-17T07:03:46Z-
dc.date.available2024-04-17T07:03:46Z-
dc.date.issued2013-
dc.identifier.citationMolecular Psychiatry, 2013, v. 18, n. 1, p. 67-78-
dc.identifier.issn1359-4184-
dc.identifier.urihttp://hdl.handle.net/10722/342432-
dc.description.abstractSchizophrenia is a severe mental disorder that affects 0.5-1% of the population worldwide. Current diagnostic methods are based on psychiatric interviews, which are subjective in nature. The lack of disease biomarkers to support objective laboratory tests has been a long-standing bottleneck in the clinical diagnosis and evaluation of schizophrenia. Here we report a global metabolic profiling study involving 112 schizophrenic patients and 110 healthy subjects, who were divided into a training set and a test set, designed to identify metabolite markers. A panel of serum markers consisting of glycerate, eicosenoic acid, β-hydroxybutyrate, pyruvate and cystine was identified as an effective diagnostic tool, achieving an area under the receiver operating characteristic curve (AUC) of 0.945 in the training samples (62 patients and 62 controls) and 0.895 in the test samples (50 patients and 48 controls). Furthermore, a composite panel by the addition of urine β-hydroxybutyrate to the serum panel achieved a more satisfactory accuracy, which reached an AUC of 1 in both the training set and the test set. Multiple fatty acids and ketone bodies were found significantly (P0.01) elevated in both the serum and urine of patients, suggesting an upregulated fatty acid catabolism, presumably resulting from an insufficiency of glucose supply in the brains of schizophrenia patients. © 2013 Macmillan Publishers Limited.-
dc.languageeng-
dc.relation.ispartofMolecular Psychiatry-
dc.subjectbiomarker-
dc.subjectGC-TOFMS-
dc.subjectmetaobonomics-
dc.subjectNMR-
dc.subjectschizophrenia-
dc.titlePotential metabolite markers of schizophrenia-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/mp.2011.131-
dc.identifier.pmid22024767-
dc.identifier.scopuseid_2-s2.0-84871291341-
dc.identifier.volume18-
dc.identifier.issue1-
dc.identifier.spage67-
dc.identifier.epage78-
dc.identifier.eissn1476-5578-
dc.identifier.isiWOS:000312771600013-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats